Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone
ESMO Virtual Congress 2020
Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in the metastatic setting with palbociclib plus endocrine therapy did not translate into the earlier adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer. Long-term follow-up is ongoing (Abstract LBA12).
The ASCO Post Staff
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses the first results from the phase III CheckMate 9ER trial, which suggested the combination of nivolumab and cabozantinib is safe. It showed activity in progression-free and overall survival, as well as in overall response rates and may have a place in treating patients with metastatic renal cell carcinoma (Abstract 696O_PR).
The ASCO Post Staff
Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses results of the phase II PRINCEPS trial, which assessed, for the first time, the effect of just one injection of the immunotherapy atezolizumab before surgery in patients with resectable non–small cell lung cancer (Abstract 1215O).
The ASCO Post Staff
Alexander M. Eggermont, MD, PhD, of the Princess Maxima Center for Pediatric Oncology, discusses final results of the phase III EORTC 1325-MG/Keynote 054 trial, which confirmed a sustained recurrence-free survival benefit of pembrolizumab vs placebo in patients with resected high-risk stage III melanoma, as well as a decrease in the incidence of distant and locoregional recurrence (Abstract LBA46).
The ASCO Post Staff
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research, London, discusses long-term STAMPEDE trial results that showed patients with metastatic, hormone-naive prostate cancer benefited from abiraterone acetate plus prednisolone in terms of overall and failure-free survival, as well as skeletal-related events (Abstract 611O).
The ASCO Post Staff
Andreas du Bois, MD, PhD, of Kliniken Essen Mitte, discusses the NORA and INOVATYON studies of patients with recurrent ovarian cancer, detailing the findings for women in China with platinum-sensitive disease and women internationally who received trabectedin and pegylated liposomal doxorubicin (PLD) followed by platinum at disease progression vs carboplatin and PLD after disease progression (Abstract LBA29 and LBA30).
